Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
31.07 (1y: +58%)
Market Cap 849.21 M P/E(ttm) 20.10
Enterprise Value 847.08 M P/B 3.60
BRLI- NAS (USA)
Bio-Reference Labs, Inc.
  • Currently 5/5
Business Predictability Rank: 5-Star
Back Testing Results:
Average gain of all 5-Star stocks: 12.1% per year.
% of Stocks that are in still loss if held for 10yrs: 3%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$31.07
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt 1.393
BRLI's Cash to Debt is ranked lower than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. BRLI: 1.393 )
BRLI' s 10-Year Cash to Debt Range
Min: 0.03   Max: 1.39
Current: 1.39
0.03
1.39
Equity to Asset 0.631
BRLI's Equity to Asset is ranked higher than
64% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. BRLI: 0.631 )
BRLI' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.63
Current: 0.63
0.11
0.63
Interest Coverage 58.9
BRLI's Interest Coverage is ranked higher than
53% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. BRLI: 58.9 )
BRLI' s 10-Year Interest Coverage Range
Min: 1   Max: 59
Current: 58.9
1
59
F-Score: 6
Z-Score: 9.23
M-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 11.50
BRLI's Operating margin (%) is ranked higher than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. BRLI: 11.50 )
BRLI' s 10-Year Operating margin (%) Range
Min: -6.5   Max: 11.5
Current: 11.5
-6.5
11.5
Net-margin (%) 6.4
BRLI's Net-margin (%) is ranked higher than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. BRLI: 6.4 )
BRLI' s 10-Year Net-margin (%) Range
Min: -9.3   Max: 6.5
Current: 6.4
-9.3
6.5
ROE (%) 18.6
BRLI's ROE (%) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. BRLI: 18.6 )
BRLI' s 10-Year ROE (%) Range
Min: -43.5   Max: 21.8
Current: 18.6
-43.5
21.8
ROA (%) 13.5
BRLI's ROA (%) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. BRLI: 13.5 )
BRLI' s 10-Year ROA (%) Range
Min: -15.5   Max: 13.5
Current: 13.5
-15.5
13.5
ROC (Joel Greenblatt) (%) 42.00
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.00 vs. BRLI: 42.00 )
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25.5   Max: 42
Current: 42
-25.5
42
Revenue Growth (%) 16.2
BRLI's Revenue Growth (%) is ranked higher than
92% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. BRLI: 16.2 )
BRLI' s 10-Year Revenue Growth (%) Range
Min: 1.1   Max: 16.4
Current: 16.2
1.1
16.4
EBITDA Growth (%) 17.7
BRLI's EBITDA Growth (%) is ranked higher than
93% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.85 vs. BRLI: 17.7 )
BRLI' s 10-Year EBITDA Growth (%) Range
Min: 16.7   Max: 26.1
Current: 17.7
16.7
26.1
EPS Growth (%) 17.8
BRLI's EPS Growth (%) is ranked higher than
93% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.90 vs. BRLI: 17.8 )
BRLI' s 10-Year EPS Growth (%) Range
Min: 10.4   Max: 167.2
Current: 17.8
10.4
167.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

BRLI Guru Trades in Q2 2012

Joel Greenblatt 65,886 sh (+14.77%)
Mario Gabelli 46,400 sh (+8.41%)
Jean-Marie Eveillard 12,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 20,800 sh (-50.72%)
» More
Q3 2012

BRLI Guru Trades in Q3 2012

Paul Tudor Jones 20,400 sh (New)
Jim Simons 22,404 sh (+7.71%)
Mario Gabelli 49,200 sh (+6.03%)
Jean-Marie Eveillard 12,000 sh (unchged)
Joel Greenblatt 57,564 sh (-12.63%)
» More
Q4 2012

BRLI Guru Trades in Q4 2012

Jim Simons 268,804 sh (+1099.8%)
Joel Greenblatt 85,579 sh (+48.67%)
Jean-Marie Eveillard 12,000 sh (unchged)
Mario Gabelli 47,800 sh (-2.85%)
Paul Tudor Jones 15,800 sh (-22.55%)
» More
Q1 2013

BRLI Guru Trades in Q1 2013

Chase Coleman 220,000 sh (New)
John Hussman 116,000 sh (New)
Paul Tudor Jones 30,600 sh (+93.67%)
Joel Greenblatt 104,240 sh (+21.81%)
Jean-Marie Eveillard 12,000 sh (unchged)
Mario Gabelli 46,800 sh (-2.09%)
Jim Simons 108,104 sh (-59.78%)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-03-31 New Buy0.11%$24.91 - $31.05 $ 30.6311%116000
Joel Greenblatt 2013-03-31 Add 21.81%0.03%$24.91 - $31.05 $ 30.6311%104240
Joel Greenblatt 2012-12-31 Add 48.67%0.05%$24.68 - $32.42 $ 30.637%85579
Joel Greenblatt 2012-03-31 New Buy0.12%$16.27 - $23.76 $ 30.6363%57406
Mario Gabelli 2011-06-30 Add 27.78%$20.57 - $25.24 $ 30.6332%36800
Jean-Marie Eveillard 2010-12-31 New Buy$20.24 - $22.79 $ 30.6343%10000
Mario Gabelli 2010-09-30 New Buy$18.51 - $22.04 $ 30.6350%36500
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Bio-Reference Labs, Inc.

Buffett-Munger Model Portfolio Posts Fourth Solid Year, Hits Refresh for 2013
December 14, 2012
Warren Buffett - Buffett-Munger Model Portfolio Posts Fourth Solid Year, Hits Refresh For 2013
The Buffett-Munger Model Portfolio, created by GuruFocus to mirror Warren Buffett and Charlie Munger's time-proven investment principles, has had an exceptional run for four years. It beat the S&P 500 the first three years after inception and narrowly missed this year, returning 12.68% compared to 13.59% for the S&P 500, since Jan. 1, 2012. Now is a good time to sign up for the annually rebalanced portfolio, since its next rebalance will take place on Jan. 1, 2013. Every year, GuruFocus selects the stocks that have the lowest PEG ratios (PEG = Price/5-Year EBITDA Growth Rate) for the Buffett-Munger portfolio. Read more...
Buffett-Munger Model Portfolio Continues Its Outperformance
July 26, 2012
- Buffett-Munger Model Portfolio Continues Its Outperformance
Focusing on Predictable High Quality Companies, GuruFocus Value Strategies Continue to Outperform. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.10
BRLI's P/E(ttm) is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.95 vs. BRLI: 20.10 )
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34   Max: 215.6
Current: 20.1
9.34
215.6
P/B 3.60
BRLI's P/B is ranked lower than
56% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BRLI: 3.60 )
BRLI' s 10-Year P/B Range
Min: 0.79   Max: 8.93
Current: 3.6
0.79
8.93
P/S 1.30
BRLI's P/S is ranked higher than
77% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. BRLI: 1.30 )
BRLI' s 10-Year P/S Range
Min: 0.16   Max: 2.44
Current: 1.3
0.16
2.44
PFCF 23.60
BRLI's PFCF is ranked higher than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. BRLI: 23.60 )
BRLI' s 10-Year PFCF Range
Min: 10.52   Max: 958
Current: 23.6
10.52
958
EV-to-EBIT 10.5
BRLI's EV-to-EBIT is ranked higher than
88% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. BRLI: 10.5 )
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 34
Current: 10.5
5.9
34
PEG 0.8
BRLI's PEG is ranked higher than
99% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. BRLI: 0.8 )
BRLI' s 10-Year PEG Range
Min: 0.38   Max: 1.37
Current: 0.8
0.38
1.37
Shiller P/E 30
BRLI's Shiller P/E is ranked higher than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.19 vs. BRLI: 30 )
BRLI' s 10-Year Shiller P/E Range
Min: 15.23   Max: 180
Current: 30
15.23
180

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 7.2
BRLI's Price/Net Current Asset Value is ranked higher than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. BRLI: 7.2 )
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 1.2   Max: 8.7
Current: 7.2
1.2
8.7
Price/Tangible Book 4.4
BRLI's Price/Tangible Book is ranked higher than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. BRLI: 4.4 )
BRLI' s 10-Year Price/Tangible Book Range
Min: 3.5   Max: 9.8
Current: 4.4
3.5
9.8
Price/DCF (Projected) 2.3
BRLI's Price/DCF (Projected) is ranked lower than
60% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. BRLI: 2.3 )
BRLI' s 10-Year Price/DCF (Projected) Range
Min: 2.1   Max: 7.8
Current: 2.3
2.1
7.8
Price/Median PS Value 1
BRLI's Price/Median PS Value is ranked higher than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. BRLI: 1 )
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 1.6
Current: 1
0.2
1.6
Price/Peter Lynch Fair Value 0.8
BRLI's Price/Peter Lynch Fair Value is ranked higher than
88% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. BRLI: 0.8 )
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.6   Max: 3.3
Current: 0.8
0.6
3.3
Price/Graham Number 2
BRLI's Price/Graham Number is ranked higher than
82% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. BRLI: 2 )
BRLI' s 10-Year Price/Graham Number Range
Min: 1.6   Max: 6.7
Current: 2
1.6
6.7
Earnings Yield (Greenblatt) 9.50
BRLI's Earnings Yield (Greenblatt) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. BRLI: 9.50 )
BRLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.9   Max: 16.9
Current: 9.5
2.9
16.9
Forward Rate of Return (Yacktman) 26.6
BRLI's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. BRLI: 26.6 )
BRLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.5   Max: 33.8
Current: 26.6
-2.5
33.8

Business Description

Bio-Reference Laboratories, Inc., is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It mainly focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. The Company currently process approximately 6.7 million laboratory test requisitions each year. It has a network of 98 patient service centers located in the Northeast (mainly in New York metropolitan super-regional area) for collection of patient specimens. It currently conducts business in most New York State counties, as well as in most of New Jersey and Maryland as well as some parts of Pennsylvania, Delaware and Connecticut. It mainly offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, extensive phlebotomy services and phlebotomy draw stations scattered around its geographic area. The Company also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. It uses this portal itself to provide laboratory ordering and results as well as connectivity to its physician customers. It also markets and licenses this connectivity solution to other laboratories throughout the country. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its major competitors in the New York metropolitan area are Quest Diagnostics and Laboratory Corporation of America. The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX
» More Articles for BRLI

Headlines

Articles On GuruFocus.com
Super-Fast Growing Mid-Cap Growth Stocks with Explosive Returns May 09 2013 
5 Ways to See Why Bio-Reference Labs Is a Solid Stock Mar 29 2013 
Buffett-Munger Model Portfolio Posts Fourth Solid Year, Hits Refresh for 2013 Dec 14 2012 
Buffett-Munger Strategy: What Worked? What Didn’t Oct 19 2012 
Buffett-Munger Model Portfolio Gained 18.2% Year-to-Date Oct 02 2012 
Buffett-Munger Model Portfolio Gained 16.1% Year-to-Date Sep 05 2012 
Buffett-Munger Model Portfolio Continues Its Outperformance Jul 26 2012 
Buffett-Munger Model Portfolio Outperforms Again - June Model Portfolio Performance Update Jun 05 2012 
Focusing on Predictable Companies, Value Strategies Continue to Outperform. Apr 02 2012 
Do You Average Down? Guru Strategy Series (I) Mar 20 2012 

More From Our Partners
How Dangerous are Five of the Most Heavily Shorted Small Cap Stocks? May 17 2013 - BENZINGA

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial